[
    [
        {
            "time": "",
            "original_text": "医药行业动态研究周报(A股及港股)：继续看好年报及疫情主线",
            "features": {
                "keywords": [
                    "医药",
                    "年报",
                    "疫情",
                    "A股",
                    "港股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业动态研究周报(A股及港股)：继续看好年报及疫情主线",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2021年春季投资策略：供需皆强劲 业绩开门红",
            "features": {
                "keywords": [
                    "医药",
                    "2021",
                    "春季",
                    "投资策略",
                    "供需",
                    "业绩",
                    "开门红"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2021年春季投资策略：供需皆强劲 业绩开门红",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药与健康护理行业周报：国内疫情向好 仍需紧密关注防控政策",
            "features": {
                "keywords": [
                    "医药",
                    "健康护理",
                    "疫情",
                    "防控政策"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "健康护理"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药与健康护理行业周报：国内疫情向好 仍需紧密关注防控政策",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本概念股多数调整，公牛集团、健帆生物、凯莱英、泰格医药、恩捷股份领跌",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "概念股",
                    "调整",
                    "公牛集团",
                    "健帆生物",
                    "凯莱英",
                    "泰格医药",
                    "恩捷股份",
                    "领跌"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "其他"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴资本概念股多数调整，公牛集团、健帆生物、凯莱英、泰格医药、恩捷股份领跌",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【异动股】泰格医药(03347-HK)跌5.8%",
            "features": {
                "keywords": [
                    "异动股",
                    "泰格医药",
                    "下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】泰格医药(03347-HK)跌5.8%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]